Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608717 | 0.88 | MAPT (0.48) | MAPTEGFRGAACYP1A2CYP3A4 | |
| SCHEMBL15071460 | 0.86 | MAPT (0.49) | MAPTEGFRGAACYP1A2CYP3A4 | |
| SCHEMBL14609800 | 0.84 | MAPT (0.54) | MAPTEGFRGAACYP1A2CYP3A4 | |
| SCHEMBL11532393 | 0.84 | MAPT (0.57) | MAPTEGFRGAACYP1A2CYP3A4 | |
| SCHEMBL3136286 | 0.83 | MEN1 (0.50) | MAPTEGFRGAACYP1A2CYP3A4 | |
| SCHEMBL7529182 | 0.81 | POLB (0.51) | MAPTCYP4F2CYP4A11KMT2AKDM4E | |
| SCHEMBL15287024 | 0.81 | MAPT (0.48) | MAPTEGFRGAACYP1A2CYP3A4 | |
| SCHEMBL4937209 | 0.80 | MAPT (0.42) | MAPTEGFRGAACYP1A2CYP3A4 | |
| SCHEMBL7073191 | 0.80 | MAPT (0.47) | MAPTEGFRKMT2AMEN1KDM4E | |
| SCHEMBL5499901 | 0.80 | ABL1 (0.54) | MAPTEGFRGAACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101356164-A | Novel compounds | ASTRAZENECA AB (SE) | 2009-01-28 | — | — | CN | disclosed |
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1948630-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007052023-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255150-A1 | Novel Compounds | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | MAPT 3534/4885EGFR 1717/4885CYP4F2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.